{"id":380297,"date":"2020-11-12T16:09:09","date_gmt":"2020-11-12T21:09:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380297"},"modified":"2020-11-12T16:09:09","modified_gmt":"2020-11-12T21:09:09","slug":"armata-pharmaceuticals-announces-third-quarter-2020-results-and-provides-general-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-announces-third-quarter-2020-results-and-provides-general-corporate-update\/","title":{"rendered":"Armata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MARINA DEL REY, Calif.<\/span>, Nov. 12, 2020<\/span> \/PRNewswire\/ —\u00a0Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the third quarter of 2020 and provided a corporate and clinical update. \u00a0<\/p>\n

\n

\n
\n \"Armata
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Subsequent to the end of the third quarter, Armata announced FDA clearance of its Investigational New Drug (IND) application to initiate a clinical trial of its lead clinical candidate, AP-PA02, in Pseudomonas aeruginosa<\/i> infections.\u00a0 <\/p>\n

“With FDA clearance of our IND, we are moving quickly to initiate a Phase 1b<\/span>\/2a clinical trial of AP-PA02 in cystic fibrosis patients suffering from Pseudomonas aeruginosa<\/i> infections, known as the SWARM-P.a.<\/i> study, and we remain on track to do so by the end of this year,” stated Todd R. Patrick<\/span>, Chief Executive Officer of Armata. “We are also rapidly advancing our second clinical candidate, AP-SA02, for difficult-to-treat Staphylococcus aureus<\/i> infections. With our growing clinical-stage pipeline, we recently strengthened our team with the addition of Dr. Mina Pastagia<\/span> as Vice President of Clinical Development.” <\/p>\n

“Multi-drug resistant bacterial infections are a serious and growing public health threat, and with two strong therapeutic candidates and a robust team that will drive clinical development, we believe we are well positioned to be a leader in the innovative field of phage therapy which is poised to transform antimicrobial intervention. Further, we are pleased with our current financial position. We ended the quarter with approximately $16 million<\/span> in cash and, to date, we have only drawn on $1.3 million<\/span> of the $20 million<\/span> in non-dilutive contract awards we received earlier this year,” Mr. Patrick concluded.<\/p>\n

\n Anticipated 2020 and 2021 Milestones:<\/b>\n <\/p>\n